Engins, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Elixirgen, LLC (to 2026)
0
Ending by 2030
Mar 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 14, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,186,621 | Methods for Enhancing the Pluripotency of Stem Cells In force · High confidence | In force | High confidence | |
| US 9,932,560 | Use of ZSCAN4 and ZSCAN4-DEPENDENT Genes for Direct Reprogramming of Somatic Cells In force · High confidence | In force | High confidence | |
| US 10,273,458 | ZSCAN4 as a Marker for Pancreatic Stem Cells and Progenitor Cells and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,059,869 | Compositions for Enhancing the Pluripotency of Stem Cells In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.